{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:02:53Z","timestamp":1771470173537,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anaplastic thyroid carcinoma is a highly lethal subtype of thyroid cancer without effective therapies. Drug resistance in anaplastic thyroid carcinoma poses a significant problem. Although artemisinin exerts antitumor effects, but its efficacy in anaplastic thyroid carcinoma is unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used RNA sequencing to identify differentially expressed genes. Next, we determined the cause of ART resistance by testing the expression and activity of \u03b2-catenin, and enhanced ART activity with a WNT signaling inhibitor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Artemisinin suppressed the growth of BHT-101 but not human thyroid anaplastic carcinoma (CAL-62) cells. The mechanism of artemisinin resistance in CAL-62 was associated with the aberrant activation of WNT signaling. Pyrvinium pamoate, an inhibitor of WNT signaling, was used to overcome ART resistance in CAL-62 cells. The combination of artemisinin and pyrvinium pamoate suppressed the growth of CAL-62 cells and induced the apoptosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study is the first to prove the efficacy of ART as monotherapy or in combination with PP in the management of anaplastic thyroid cancer, and that the inhibition of WNT signaling may overcome ART resistance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-021-03332-z","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T09:34:59Z","timestamp":1622194499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pyrvinium pamoate can overcome artemisinin\u2019s resistance in anaplastic thyroid cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Yitian","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"issue":"1","key":"3332_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"key":"3332_CR2","volume-title":"StatPearls","author":"F Limaiem","year":"2020","unstructured":"Limaiem F, Kashyap S, Giwa AO. Anaplastic Thyroid Cancer. In: StatPearls. Treasure Island: StatPearls Publishing Copyright \u00a9, StatPearls Publishing LLC; 2020."},{"issue":"3","key":"3332_CR3","first-page":"974","volume":"12","author":"M Ma","year":"2020","unstructured":"Ma M, Lin B, Wang M, Liang X, Su L, Okose O, et al. Immunotherapy in anaplastic thyroid cancer. Am J Transl Res. 2020;12(3):974\u201388.","journal-title":"Am J Transl Res"},{"issue":"4","key":"3332_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17446651.2017.1340155","volume":"12","author":"P Fallahi","year":"2017","unstructured":"Fallahi P, Ruffilli I, Elia G, Ragusa F, Ulisse S, Baldini E, et al. Novel treatment options for anaplastic thyroid cancer. Expert Rev Endocrinol Metab. 2017;12(4):279\u201388. https:\/\/doi.org\/10.1080\/17446651.2017.1340155.","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"3","key":"3332_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2016.0030","volume":"14","author":"AM Lim","year":"2016","unstructured":"Lim AM, Taylor GR, Fellowes A, Cameron L, Lee B, Hicks RJ, et al. BRAF inhibition in BRAFV600E-positive anaplastic thyroid carcinoma. J Natl Compr Cancer Netw. 2016;14(3):249\u201354. https:\/\/doi.org\/10.6004\/jnccn.2016.0030.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"9","key":"3332_CR6","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1089\/thy.2016.0072","volume":"26","author":"N Onoda","year":"2016","unstructured":"Onoda N, Sugino K, Higashiyama T, Kammori M, Toda K, Ito K, et al. The safety and efficacy of weekly paclitaxel Administration for Anaplastic Thyroid Cancer Patients: a Nationwide prospective study. Thyroid. 2016;26(9):1293\u20139. https:\/\/doi.org\/10.1089\/thy.2016.0072.","journal-title":"Thyroid"},{"issue":"6","key":"3332_CR7","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/sj.bjc.6602461","volume":"92","author":"Y Nobuhara","year":"2005","unstructured":"Nobuhara Y, Onoda N, Yamashita Y, Yamasaki M, Ogisawa K, Takashima T, et al. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer. 2005;92(6):1110\u20136. https:\/\/doi.org\/10.1038\/sj.bjc.6602461.","journal-title":"Br J Cancer"},{"issue":"13","key":"3332_CR8","doi-asserted-by":"publisher","first-page":"17194","DOI":"10.18632\/oncotarget.7839","volume":"7","author":"E Brauner","year":"2016","unstructured":"Brauner E, Gunda V, Vanden Borre P, Zurakowski D, Kim YS, Dennett KV, et al. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget. 2016;7(13):17194\u2013211. https:\/\/doi.org\/10.18632\/oncotarget.7839.","journal-title":"Oncotarget"},{"issue":"6","key":"3332_CR9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.cell.2011.08.024","volume":"146","author":"LH Miller","year":"2011","unstructured":"Miller LH, Su X. Artemisinin: discovery from the Chinese herbal garden. Cell. 2011;146(6):855\u20138. https:\/\/doi.org\/10.1016\/j.cell.2011.08.024.","journal-title":"Cell"},{"issue":"1","key":"3332_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41418-019-0352-3","volume":"27","author":"GQ Chen","year":"2020","unstructured":"Chen GQ, Benthani FA, Wu J, Liang D, Bian ZX, Jiang X. Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis. Cell Death Differ. 2020;27(1):242\u201354. https:\/\/doi.org\/10.1038\/s41418-019-0352-3.","journal-title":"Cell Death Differ"},{"key":"3332_CR11","doi-asserted-by":"publisher","first-page":"106521","DOI":"10.1016\/j.domaniend.2020.106521","volume":"74","author":"X Wang","year":"2021","unstructured":"Wang X, Meng K, Wang Y, Zhao Y, Lin F, Liu X, et al. Wilms' tumor (WT1) (+\/\u2212KTS) variants decreases the progesterone secretion of bovine ovarian theca cells. Domest Anim Endocrinol. 2021;74:106521. https:\/\/doi.org\/10.1016\/j.domaniend.2020.106521.","journal-title":"Domest Anim Endocrinol"},{"issue":"4","key":"3332_CR12","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3390\/ijms19041030","volume":"19","author":"YT Li","year":"2018","unstructured":"Li YT, Tian XT, Wu ML, Zheng X, Kong QY, Cheng XX, et al. Resveratrol suppresses the growth and enhances retinoic acid sensitivity of anaplastic thyroid cancer cells. Int J Mol Sci. 2018;19(4):1030.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3332_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12935-019-0908-9","volume":"19","author":"L Yang","year":"2019","unstructured":"Yang L, Sun R, Wang Y, Fu Y, Zhang Y, Zheng Z, et al. Expression of ANGPTL2 and its impact on papillary thyroid cancer. Cancer Cell Int. 2019;19(1):204. https:\/\/doi.org\/10.1186\/s12935-019-0908-9.","journal-title":"Cancer Cell Int"},{"issue":"35","key":"3332_CR14","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.1038\/s41388-019-0873-8","volume":"38","author":"L Li","year":"2019","unstructured":"Li L, Ameri AH, Wang S, Jansson KH, Casey OM, Yang Q, et al. EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis. Oncogene. 2019;38(35):6241\u201355. https:\/\/doi.org\/10.1038\/s41388-019-0873-8.","journal-title":"Oncogene"},{"issue":"7","key":"3332_CR15","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/cncr.20936","volume":"103","author":"E Kebebew","year":"2005","unstructured":"Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103(7):1330\u20135. https:\/\/doi.org\/10.1002\/cncr.20936.","journal-title":"Cancer"},{"issue":"10","key":"3332_CR16","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1158\/1078-0432.CCR-07-2248","volume":"14","author":"JA Engelman","year":"2008","unstructured":"Engelman JA, J\u00e4nne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2008;14(10):2895\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-2248.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3332_CR17","first-page":"4552","volume":"11","author":"J Chen","year":"2018","unstructured":"Chen J, Liu TY, Peng HT, Wu YQ, Zhang LL, Lin XH, et al. Up-regulation of Wnt7b rather than Wnt1, Wnt7a, and Wnt9a indicates poor prognosis in breast cancer. Int J Clin Exp Pathol. 2018;11(9):4552\u201361.","journal-title":"Int J Clin Exp Pathol"},{"key":"3332_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.canlet.2017.05.029","volume":"402","author":"Q Li","year":"2017","unstructured":"Li Q, Ye L, Zhang X, Wang M, Lin C, Huang S, et al. FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt\/\u03b2-catenin signaling. Cancer Lett. 2017;402:166\u201376. https:\/\/doi.org\/10.1016\/j.canlet.2017.05.029.","journal-title":"Cancer Lett"},{"issue":"11","key":"3332_CR19","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36(11):1461\u201373. https:\/\/doi.org\/10.1038\/onc.2016.304.","journal-title":"Oncogene"},{"issue":"8","key":"3332_CR20","doi-asserted-by":"publisher","first-page":"djw332","DOI":"10.1093\/jnci\/djw332","volume":"109","author":"L Zhang","year":"2017","unstructured":"Zhang L, Shay JW. Multiple roles of APC and its therapeutic implications in colorectal cancer. J Natl Cancer Inst. 2017;109(8):djw332.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"3332_CR21","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1002\/jcp.26006","volume":"233","author":"AA Momtazi-Borojeni","year":"2018","unstructured":"Momtazi-Borojeni AA, Abdollahi E, Ghasemi F, Caraglia M, Sahebkar A. The novel role of pyrvinium in cancer therapy. J Cell Physiol. 2018;233(4):2871\u201381. https:\/\/doi.org\/10.1002\/jcp.26006.","journal-title":"J Cell Physiol"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-021-03332-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-021-03332-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-021-03332-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T09:35:09Z","timestamp":1622194509000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-021-03332-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3332"],"URL":"https:\/\/doi.org\/10.1186\/s12906-021-03332-z","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"assertion":[{"value":"14 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares that he has no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}